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them harder to detect) it could cause an apparent
excess stroke incidence and survival advantage in black
people.
Alternatively, can the findings be explained by
residual confounding? Black patients in the south
London register were younger (by about 10 years), had
a higher proportion of lacunar ischaemic strokes
(which have a very low case fatality), and were more
likely to be admitted to hospital and be cared for on a
stroke unit,5 all of which would tend to improve
survival. However, the survival advantage persisted
after adjustment for demographic variables, socioeco-
nomic status, prior risk factors and their management,
stroke severity, and acute stroke management. Adjust-
ment for stroke severity in particular may have been
incomplete as analyses were stratified by the main
pathological types of stroke (ischaemic stroke, intracer-
ebral haemorrhage, and subarachnoid haemorrhage),
but it is unclear whether adjustment for the
distributions of ischaemic stroke subtypes was under-
taken.
However, the combination of differential case
ascertainment and residual confounding could prob-
ably not explain all of the difference in survival, so what
could explain a genuine ethnic difference? Subgroup
analyses found that the difference was confined to
older patients and those with minimal disability before
their stroke,5 but as only 166 black patients died this
could be a chance finding. The authors propose that
better control of risk factors among black patients may
partly explain their better survival, and that the
migrant population from Africa and the Caribbean
may be particularly healthy.5 But this would not explain
the increased incidence of stroke in black people. Like
studies in the US,11 12 the south London register found
a higher prevalence of hypertension and diabetes and
a lower prevalence of ischaemic heart disease and
atrial fibrillation in black stroke patients than in white
ones. Such differences in risk factors may differentially
influence particular causes of death after stroke, such
as recurrent stroke or myocardial infarction. Finally,
black patients could have better community care provi-
sion than white patients. Although the south London
register’s researchers have found no clear difference in
the provision of NHS care after stroke between ethnic
groups,13 they have not yet studied the care provided by
families and other social networks, which may differ
between ethnic groups.
The results are intriguing, and should encourage
further studies of these possible explanations in south
London and elsewhere.
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Cardiac impairment or heart failure?
“Heart failure” confuses doctors and patients and needs renaming
“There is no disease that you either have ordon’t have—except perhaps sudden deathor rabies. All other diseases you either have
a little or a lot of,” said Geoffrey Rose.1 This is true of
“heart failure”—everybody can have a bit if they try
hard enough, by physical exertion or even by
emotional shock.2 But, apart from transient induced
cardiac overload, the term can be used to mean
anything from asymptomatic systolic dysfunction to
imminent death from pulmonary oedema. Because of
widely varying definitions, the epidemiology of heart
failure can become almost uninterpretable, with
estimates of its prevalence in the United Kingdom
varying from 500 000 to 3 million.3 Moreover, qualita-
tive studies show that many patients are never told that
they have heart failure because doctors are under-
standably reluctant to use the term.4 When a label
confuses doctors and impairs communication with
patients, it seems sensible to change the label.
The recent increase in interest in heart failure
began with interventional studies among highly
selected patients. They were mainly men aged 60-65 on
average, with a history of myocardial infarction or car-
diomyopathy and a left systolic ejection fraction of less
than 30-35% as measured by cardiac catherisation or
radionuclide ventriculography. After initial success in
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treating such patients with angiotensin converting
enzyme inhibitors, a series of other drugs were tried,
usually by addition and using similar selection criteria.
These trials have left us a valuable legacy of evidence
on the best ways to slow the progression of systolic
heart failure in younger men, mainly because of
ischaemia. However, most patients with a syndrome of
heart failure are not like this.5 Their average age in
general practice in the UK is 77,6 and they mostly have
considerable comorbidity. The proportions of women
and men even out with age, as do the proportions with
and without systolic dysfunction.
To identify patients with heart failure who
correspond to the group for which we have an
evidence base, clinicians and service providers have
focused on improving access to echocardiography.
But echocardiography alone cannot diagnose heart
failure: it is not the “gold standard.” None of the early
and important interventional trials used echocardio-
graphy to measure systolic ejection fraction because,
although it is relatively cheap and accessible, several
other methods are more accurate. Echocardiography
is an essential tool in assessing the status and severity
of heart failure and provides a wealth of structural and
dynamic information. But heart failure remains a
clinical diagnosis, and functional status and prognosis
bear little relation to the ejection fraction alone. In a
recent European study researchers, like many
clinicians, used an ejection fraction of 50% to define
“systolic dysfunction.” They found no difference in
10 year survival among patients with ejection fractions
above and below this level.7 Similar outcomes
have also been reported in hospital patients in the
UK, using ejection fraction of 40% as the cut-off
point.8
Heart failure is found chiefly in elderly people who
may or may not have impairment of systolic function
that is measurable by echocardiography. As every
clinician knows, such patients often go in and out of
overt heart failure. Because heart failure is a
continuum, its definition should be based on the best
marker for prognosis. There is little doubt that the best
single marker is the level of the cardiac hormone,
B-type natriuretic peptide, in blood: measured on a
single occasion, it outperforms all other tests,
including the systolic ejection fraction and more com-
prehensive echocardiographic measures, such as the
Tei index.9 Measuring B-type natriuretic peptide
sequentially to determine average serum concentra-
tions or the rate of their change will probably prove
even more predictive because this hormone responds
quickly to changes in cardiac load. Moreover, evidence
is increasing that this hormone could be a much
needed marker of response to treatment for heart fail-
ure in individual patients.
It is hard to overstate the value of a simple, repeat-
able, and highly predictive blood test in guiding the
treatment of heart failure. Such a test could give
patients with heart failure access to the kind of chronic
disease management that works successfully in
primary care for diabetes and for secondary preven-
tion in coronary heart disease. But before this can
become a reality, we need more long term studies of
B-type natriuretic peptide as a predictor of response to
treatment: several are in progress.10 Also, by routinely
measuring this hormone in patients at risk of heart
failure—those with ischaemic heart disease, high blood
pressure, and diabetes—we may be able to prevent or
delay the onset of symptomatic heart failure in many of
such patients.
B-type natriuretic peptide is a reliable indicator
of a struggling heart. Anything which strains or
inflames either of the cardiac ventricles increases its
serum concentrations, and conversely those levels are
not elevated in the absence of ventricular strain or
inflammation. In individual patients, further investiga-
tion may need to be done to determine the cause of
that struggle, but the more we use B-type natriuretic
peptide in clinical management, the more we will
tend to redefine our concept of “heart failure” and
may begin to wonder whether this a helpful label
at all.
For doctors, “heart failure” covers a confusingly
wide spectrum of illness, whereas for patients it has a
deadly ring of finality.11 Failure means the end of hope,
and many patients who have been told they have heart
failure prefer not to remember the term or let it domi-
nate their lives. This partial denial may have damaging
consequences, both psychologically and in terms of
adherence to treatment.12 Given that we already have
so much trouble deciding on a definition of heart fail-
ure ourselves, it might be kinder, and more accurate, to
start calling it cardiac impairment.
Richard Lehman general practitioner
Hightown Surgery, Hightown Gardens, Banbury, Oxfordshire
OX16 9DB
richard.lehman@gp-k84059.nhs.uk
Jenny Doust senior research fellow in clinical epidemiology
Division of Health Systems, Policy and Practice, University of
Queensland, Level 2, Edith Cavell Building, Royal Brisbane Hospital
Complex, QLD 4029, Australia
Paul Glasziou director
Centre for Evidence-Based Practice, Oxford University, Oxford
OX3 7LF
Competing interests: None declared.
1 Rose G. The strategy of preventive medicine. Oxford: Oxford University
Press, 1992:72.
2 Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP,
Gerstenblith G, et al. Neurohumoral features of myocardial stunning due
to sudden emotional stress. N Engl J Med 2005;352:539.
3 Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how
big is it? Eur Heart J 2001;8:623-6.
4 Murray SA, Boyd K, Kendall M, Worth A, Benson TF, Clausen H.
Dying of lung cancer or cardiac failure: prospective qualitative interview
study of patients and their carers in the community. BMJ 2002;325:
929-32.
5 Masoudi FA,Havranek EP,Wolfe P, Gross CP, Rathore SS, Steiner JF, et al.
Most hospitalized older persons do not meet the enrollment criteria for
clinical trials in heart failure. Am Heart J 2003;146:250-7.
6 de Guili F, Khaw KT, Cowie MR, Sutton GC, Ferrari R, Poole-Wilson PA.
Incidence and outcome of persons with a clinical diagnosis of heart fail-
ure in a general practice population of 696,884 in the United Kingdom.
Eur J Heart Fail 2005;7:295-302.
7 Varela-Roman A, Grigorian L, Bassante P, de la Pena MG,
Gonzalez-Juanatey JR. Heart failure in patients with preserved and
deteriorated left ventricular ejection fraction. Heart 2005;91:489-94.
8 Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart fail-
ure with preserved left ventricular systolic function: a hospital cohort
study. Heart 2005;91:907-13.
9 Doust J, Pietrzak E, Dobson A, Glasziou PP. How well does BNP predict
death and cardiac events in patients with heart failure: a systematic
review. BMJ 2005;330:625-34.
10 Richards AM, Troughton R, Lainchbury J, Doughty R, Wright S. Guiding
and monitoring of heart failure therapy with NT-proBNP: concepts and
clinical studies. J Card Fail 2005;11(suppl5):S34.
11 Tayler M, Ogden J. Doctors’ use of euphemisms and their impact on
patients’ beliefs about health: an experimental study of heart failure.
Patient Educ Couns 2005;57:321-6.
12 Buetow SA, Coster GD. Do general practice patients with heart failure
understand its nature and seriousness, and want improved information?
Patient Educ Couns 2001;45:181-5.
Editorials
416 BMJ VOLUME 331 20-27 AUGUST 2005 bmj.com
 on 14 November 2007 bmj.comDownloaded from 
